You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

 

Online download statistics by month:

Online download statistics by month: April 2024 to January 2026

AbstractFullPdf
Apr 2024602608243
May 2024307310122
Jun 202422823081
Jul 202424424480
Aug 202417817761
Sep 202414314666
Oct 202414214246
Nov 202416616748
Dec 202419319555
Jan 202518619365
Feb 202515815856
Mar 202512012069
Apr 202512812876
May 202510910957
Jun 2025838346
Jul 2025110
Sep 2025110
Jan 2026100
Total299030121171